The New York Entrepreneur

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

Read Time:6 Second

Some patients with obstructive sleep apnea and obesity who took the highest dose of Zepbound achieved “disease resolution” in the two trials.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Retail investors are having a pretty good year. Here’s why that could continue no matter what happens next.
Next post How a Florida traffic stop unraveled a multistate unemployment-benefit scam